

Serine/Threonine Protein Kinase Pim 2 - Pipeline Review, H1 2020

<https://marketpublishers.com/r/S11884C71E51EN.html>

Date: January 2020

Pages: 44

Price: US\$ 3,500.00 (Single User License)

ID: S11884C71E51EN

Abstracts

Serine/Threonine Protein Kinase Pim 2 - Pipeline Review, H1 2020

SUMMARY

Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) pipeline Target constitutes close to 10 molecules. The latest report Serine/Threonine Protein Kinase Pim 2 - Pipeline Review, H1 2020, outlays comprehensive information on the Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) - Serine/threonine-protein kinase Pim-2 is an enzyme encoded by the PIM2. It is involved in cell survival and cell proliferation. It regulates cap-dependent protein translation in a mammalian target of rapamycin complex 1 (mTORC1)-independent manner and in parallel to the PI3K-Akt pathway. It mediates survival signaling through phosphorylation of BAD, which induces release of the anti-apoptotic protein Bcl-X (L)/BCL2L1.

It promotes cell survival in response to a variety of proliferative signals via positive regulation of the I-kappa-B kinase/NF-kappa-B cascade. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 6 and 2 respectively. Report covers products from therapy areas Oncology which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Hematological Tumor, Pancreatic Cancer, Solid Tumor, Acute Lymphocytic Leukemia

(ALL, Acute Lymphoblastic Leukemia), Bladder Cancer, Breast Cancer, Chronic Lymphocytic Leukemia (CLL), Colon Cancer, Diffuse Large B-Cell Lymphoma, Liver Cancer, Lung Cancer, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Disorders, Non-Small Cell Lung Carcinoma, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary Myelofibrosis, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma and Secondary Myelofibrosis.

Furthermore, this report also reviews key players involved in Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1)

The report reviews Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Serine/Threonine Protein Kinase Pim

2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) - Overview

Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) - Companies Involved in Therapeutics Development

Amgen Inc

Incyte Corp

Inflection Biosciences Ltd

Jasco Pharmaceuticals LLC

Novartis AG

Sanofi

Tolero Pharmaceuticals Inc

Yakult Honsha Co Ltd

Zovis Pharmaceuticals

Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) - Drug Profiles

Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) - Dormant Products

Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) - Discontinued Products

Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) - Product Development Milestones

Featured News & Press Releases

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Amgen Inc, H1 2020
Pipeline by Incyte Corp, H1 2020
Pipeline by Inflection Biosciences Ltd, H1 2020
Pipeline by Jasco Pharmaceuticals LLC, H1 2020
Pipeline by Novartis AG, H1 2020
Pipeline by Sanofi, H1 2020
Pipeline by Tolero Pharmaceuticals Inc, H1 2020
Pipeline by Yakult Honsha Co Ltd, H1 2020
Pipeline by Zovis Pharmaceuticals, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020

COMPANIES MENTIONED

Amgen Inc
Incyte Corp
Inflection Biosciences Ltd
Jasco Pharmaceuticals LLC
Novartis AG
Sanofi
Tolero Pharmaceuticals Inc
Yakult Honsha Co Ltd
Zovis Pharmaceuticals

I would like to order

Product name: Serine/Threonine Protein Kinase Pim 2 - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/S11884C71E51EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S11884C71E51EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970